Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 180; pp. 85 - 88
Main Authors Kasper, Stefan, Foch, Caroline, Esser, Regina, Lamy, Francois-Xavier, Zhang, Aimar, Cheng, Ann-Lii, Rouyer, Magali, Brodowicz, Thomas, Zielinski, Christoph
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2023
Elsevier Science Ltd
Subjects
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cetuximab - therapeutic use
Colonic Neoplasms - drug therapy
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Humans
Metastases
Proto-Oncogene Proteins p21(ras)
Rectal Neoplasms - drug therapy
Tumors
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2022.11.021